Original Articles

Pediatric CNS imaging and long-term effects of irradiation in pediatric oncology patients

Sara Kluge,1 Panagiotis Balermas,2,3 Thomas Lehnbecher4 and Luciana Porto1

1Institute of Neuroradiology, Frankfurt, 2Department of Radiation Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany, 3Department of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland and 4Division for Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany

Abstract

Background: The aim of this study was to evaluate post-irradiation changes in the central nervous system (CNS) detected using magnetic resonance (MR) imaging.

Methods: Magnetic resonance images of 15 children with CNS tumors treated through whole-brain irradiation over 10 years were reviewed retrospectively. Variables such as age at the time of irradiation, total radiation dose, treatment length, and time interval between irradiation and MR changes, were evaluated.

Results: All patients included in the study had imaging abnormalities of the CNS. Eight patients (53%) developed CNS abnormalities within a short period of time – only a few months after irradiation (mean 4.8 months). Seven patients (47%) developed CNS abnormalities within a long time interval after treatment (mean 4.6 years). In almost all patients, a T2 increase in supra- and infratentorial white matter was observed. Follow-up examinations showed nine patients (60%) with cerebellar atrophy.

Conclusions: In this sample of pediatric patients who underwent whole-brain irradiation, the time receiving irradiation was not related to the severity of the MR changes. A correlation between the age of the child or the length of the radiotherapy and the extent of the changes could not be confirmed. However, we observed a trend towards stronger brain parenchymal degeneration with cystic changes in the younger age group of children in our sample. Older children who received irradiation seem to be more susceptible to vascular dysplasia with cavernous hemangiomas and microbleeding.

Key words child, irradiation, MRI, oncology, pediatrics.

Primary brain tumors are the most common solid tumors in the pediatric population and account for approximately 20% of all pediatric cancers and for 53% of all central nervous system (CNS) tumors in the pediatric population.1–4 Cranial radiation therapy (CRT) is an integral part of the treatment of patients with CNS and other intracranial tumors or disorders with CNS involvement, to maintain a high cure and low relapse rate.3,4 With acute leukemia or primary brain tumors like glioma, ependymoma, medulloblastoma, pilocytic astrocytoma, neuroblastoma, and germ cell tumors, with primary CNS lymphoma, CRT is used to prevent a central nervous system relapse.5,6 Surgical removal is the treatment of choice, followed by surveillance, radiotherapy, or chemotherapy.1–3,9 As current therapeutic strategies achieve an excellent long-term survival rate, potential treatment-induced late effects are increasingly observed, which lead some authors to question the necessity for radiotherapy, especially with younger children.10 As the children’s survival rate and duration increases, the focus has shifted to the long-term effects of the therapy. Several studies have shown that neuropsychological outcomes depend on age at treatment and dose of cranial radiotherapy, and that a reduction in CRT dose may limit the effects on intellectual function.1

Usually, cranial irradiation is only carried out on patients older than 4 years because of an increased risk of severe late effects with CRT for younger patients.8 At 2–3 years of age the child’s cortex has developed 90% of its later weight, neurogenesis and gliogenesis have mostly been completed, and synaptic density has reached its peak.11 For patients under the age of 4 years, the standard method is chemotherapy.12 In rare cases, for example if the tumor is inoperable, irradiation can also be considered for children younger than 4 years of age.

Recently, concerns about the late toxic effects that might arise from radiation therapy of the whole brain in young patients led to suggestions that reduced field radiation could be adequate for the cure as well.6 Known late complications of whole-brain irradiation include a wide spectrum of...
abnormalities ranging from subclinical changes that are only detectable by magnetic resonance imaging (MRI) to endocrine dysfunction, cognitive impairment or secondary neoplasm by effects on the microenvironment that allow for growth of pre-existing malignant cells. Furthermore, the risk of developing cavernous hemangioma (CH) has already been described in several studies. It appears that all changes are likely to result from complex alterations with at least four contributing factors including damage to vessel structures, deletion of progenitor cells and mature oligodendrocytes, deletion of neural stem cells in the hippocampus, cerebellum, and cortex, and generalized alterations of cytokine expression. 

Magnetic resonance imaging of the CNS is a sensitive method and the usual procedure to diagnose adverse effects of CRT in adults as well as in pediatric patients. The aim of this study was to determine the effects of CRT (whole brain irradiation) and the extent of cerebral changes after irradiation depending on age during irradiation.

**Methods**

This retrospective review was approved by the institutional review board. Patient data were obtained from the electronic medical records including MRI data sets from the departments of neuroradiology and radiotherapy. Inclusion criteria: We performed a retrospective analysis of all pediatric patients at the Children’s Hospital of the Goethe University Frankfurt with CNS tumors, who received a whole brain irradiation in the period from January 1, 2007 to January 1, 2017 and whose data were electronically stored at the University of Frankfurt. We retrospectively analyzed the brain volume irradiated by a cumulative dose of 52.4 Gy on average (range 35.2-100 Gy) in all MRI examinations available to us. All but two patients received an additional radiation boost in the localization of the tumor. The protocols of magnetic resonance imaging examinations in this context include standard contrast-enhanced and also susceptibility-weighted sequences. Exclusion criteria were lesions of the brain parenchyma (with the exception of the primary tumor) before therapy. In addition, patients undergoing brachytherapy, radiosurgery or partial brain irradiation were not included in this study. The medical records were reviewed with attention to the age at the time of radiation therapy, the time of onset of imaging changes, and both clinical and imaging long-term outcome. Variables were compared using the $\chi^2$ test.

**Results**

Patients: A total of 15 children with brain tumors, who fulfilled these criteria and received postoperative whole-brain CRT, were included in this study. Of these, one patient with germinoma did not receive any surgical therapy before starting the irradiation – only radiochemotherapy was performed. All patients were treated with chemotherapy, too. The 15 patients consisted of 11 male and four female participants. Mean age at time of CRT was 10.5 years. By default, the retrospectively analyzed MRI images were taken quarterly during the first 2 years after irradiation. In cases of pathological changes, that observation period was extended. In one patient the time interval between the available MRI examinations was only 4 months.

Time interval to signal alterations: All of the 15 patients included in the study (100%) were found to have CNS abnormalities within the course of MRI examinations. In eight patients, the first CNS abnormalities were detected after only a few months (mean 4.8 months); the other seven patients showed the first changes after some years (mean 4.6 years). As shown in Table 1, it was not possible to establish a correlation between the age of the patient during irradiation and the exact time at which the changes were observed for the first time, except for cystic changes, which were only observed in two patients, who were under 6 years of age at the time of irradiation. However, these cystic changes were not detectable in all patients, who were younger than 6 years of age at the time of irradiation. Patients in whom signal changes in the MRI were observed at the earliest possible time (in the first MRI examination 3 months after irradiation) were 2 years, 9 years, and 12 years old at the time of irradiation. On the other hand, patients in whom the signal changes occurred at least 5 years after irradiation were 6 years, 14 years, and 16 years of age and thus these patients also had a very large age range (Table 1).

Radiation dose: There was no significant correlation between the time interval (from irradiation to the appearance of MRI signal changes) and the total radiation dose – see Table 1. The shortest time interval for a patient (age at irradiation: 6 years) with the highest radiation dose (100 Gy) was 1 year, whereas the two patients (5 and 13 years of age during irradiation) with the second highest total radiation dose of 77.4 Gy clearly differ in time intervals with 6 months and 2 years between their irradiation and first occurrence of signal changes (Table 1). The patient with the lowest radiation dose with its delay between irradiation and the first detection of post-therapeutic MRI changes of the cerebral parenchyma after an interval of 2 years was in the relative midfield compared to the delay until the first occurrence of cerebral changes in the remaining patients. (Table 1).

All patients had numerous examinations over many years between the first post-irradiogenic examination and the last examination available to us. Depending on the time interval between the follow-up examinations and the period of time since the detection of the disease, we had very different numbers and total intervals of all available follow-up examinations, whereby the total interval of the MRI examinations of each patient available to us included a minimum of 4 months and a maximum of 14 years. The median of the time intervals between onset of disease and last examination was 7.1 years. Post-radiation changes include a wide spectrum of signal abnormalities.

MRI anomalies: Considering the various parenchymal changes, 11 out of 15 patients were found to have changes of white matter with areas of increased signal intensity on T2-weighted sequences (Table 2). With eight out of these 11
Table 1  Patient data (age, diagnosis and therapy) as well as an exact list of MRI changes of the brain parenchyma at the respective examination times (time period since irradiation) and the time interval of all MRI examinations available to us

| Diagnosis                        | Surgery (yes 1, no 0) | Radiation dose | Age at radiotherapy (years) | Chemotherapy (CTX) | Period from radiatio to first MRI (months) | Signal 1. MRI | MRI with first signal changes | Period until last MRI (months) | Signal changes in last (in study included) MRI | Cysts | Time between MRI exam. | Symptoms                                      |
|----------------------------------|-----------------------|----------------|-----------------------------|--------------------|---------------------------------------------|---------------|------------------------------|--------------------------------------|---------------------------------------------|-------|--------------------------|-----------------------------------------------|
| Medulloblastoma                  | 1                     | 23.4 Gy axis + 54 Gy infratent | 16                       | 1                  | 1                                           | Normal        | 159                          | 60                                    | Normal signal, cerebellar atrophy              | 0     | 14 y                      | FrONTALlobe disorder, epilepsy                  |
| Medulloblastoma                  | 1                     | 36 Gy axis + Boost infratent 14 Gy | 6                        | 1                  | 1                                           | Normal        | 65                           | 124                                   | Increasing T2 cerebellar + pontin, no atrophy | 0     | 11 y                      | Slight palsy leg, insufficiency thyroid and pituitary gland, hearing loss |
| Medulloblastoma                  | 1                     | 40 Gy + Boost infratent 10 Gy | 8                         | 1                  | 1                                           | Normal        | 19                           | 60                                    | cm enhancement op margins, cavernoma cerebellar | 0     | 5 y                       |                                                                                           |
| Medulloblastoma                  | 1                     | 23.4 Gy axis + 30.6 infratent | 12                       | 1                  | 1                                           | Normal        | 1                           | 103                                   | Global T2-increase, cm enhancement leptomeningeal | 0     | 9 y                       | Cerebellar ataxia, intention-tremor, abduces paresis                                                                                 |
| Germinoma                        | 0                     | 23.4 Gy axis + 16.2 infratent | 21                       | 1                  | 2                                           | Normal        | 9                            | 116                                   | T2-increase colliculus inferior                 | 0     | 9 y                       | Insufficiency pituitary gland, MOTOR disabilities                                      |
| Pilocytic astrocytoma            | 1                     | 23.4 Gy + infratent 30.6 Gy | 14                       | 1                  | 1                                           | Normal        | 86                           | 134                                   | Increasing T2 tumors, meningeosis carcinomatosa since 2013 | 0     | 11 y                      |                                                                                           |
| Medulloblastoma                  | 1                     | 23.4 Gy + 54 Gy infratent | 13                       | 1                  | 5                                           | Normal        | 5                            | 48                                    | T2-increase deep white matter                  | 0     | 4 y                       | Diplopia                                      |
| Medulloblastoma                  | 1                     | 35.2 Gy axis | 5                         | 1                  | 2                                           | Normal        | 21                           | 40                                    | T2* signal loss, microbleeding                  | 0     | 3 y                       |                                                                                            |
| Medulloblastoma                  | 1                     | 23.4 Gy axis + Boost infratent 54 Gy | 5                        | 1                  | 1                                           | Normal        | 22                           | 76                                    | Cerebellar T2-increase, atrophy                  | 0     | 6 y                       |                                                                                            |
| Medulloblastoma                  | 1                     | 23.4 Gy axis + 30.6 infratent 4 Gy | 14                       | 1                  | 1                                           | Normal        | 9                            | 25                                    | T2* signal loss, atrophy                        | 0     | 2 y                       | Motor disabilities                            |
| Medulloblastoma                  | 1                     | 40 Gy axis | 9                         | 1                  | 1                                           | Normal        | 3                            | 4                                     | Slight T2-increase cerebellar and beginning Atrophy | 0     | 4 months                  | Ataxia                                        |
| Medulloblastoma                  | 1                     | 23.4 Gy axis + 30.6 Gy infratent | 13                       | 1                  | 1                                           | Normal        | 5                            | 54                                    | T2* signal loss, infratentorial T2-increase, atrophy | 0     | 6 y                       |                                                                                            |
| Atypical teratoid/rhabdoid tumor | 1                     | 35.2 Gy axis + 19.8 Gy RoI | 2                         | 1                  | 1                                           | Normal        | 2                            | 70                                    | Reduced T2-increase supratentorial              | 1     | 6 y                       |                                                                                            |
| Medulloblastoma                  | 1                     | 23.4 Gy axis + 30.6 Gy infratent | 14                       | 1                  | 1                                           | Normal        | 31                           | 105                                   | T2* signal loss, infratentorial T2-increase, atrophy | 0     | 9 y                       |                                                                                            |
| Medulloblastoma                  | 1                     | 40 Gy axis + 60 Gy infratent | 6                         | 1                  | 3                                           | Normal        | 18                           | 140                                   | T2-increase Ncl. dentatus                        | 1     | 11 y                      |                                                                                            |
patients, T2-hyperintensity was observed in the posterior fossa. In nine of 15 patients focal atrophy of the cerebral parenchyma was observed within the irradiated volume (Table 2). Contrast enhancement was evident with three of the 15 patients, which in two cases corresponded to postoperative granulation tissue and in one case to a meningioma carcinoma. The reactive enhancement decreased in one case after an interval of 6 months, while in the other case no dynamic of the enhancement was observed over a period of 2 years. With 2 patients, suspected relapse was observed during the MRI examinations. In the patient with meningioma carcinoma, the changes were detected 9 years after irradiation for the first time. In the other case, 14 years after irradiation a glioma was detected.20 Cavernomas were observed in four patients. All our included patients underwent chemotherapy. A correlation between the chemotherapy and the changes therefore cannot be assessed. The same applies to surgery: with the exception of one patient, all patients underwent surgery. Although no atrophy was found here, five patients under surgery also showed no atrophy during the period of investigation.

Discussion

Although radiotherapy is an integral part of the treatment of various forms of malignant diseases, possible delayed effects due to treatment are still alarming. However, actual data providing findings of risks are scarce, especially with respect to whole-brain irradiation. Computed tomography (CT) scans were used for monitoring purposes before the widespread availability of MRI equipment. Nowadays monitoring is usually carried out using MRI. O Robin et al. described necrotizing changes in the brain parenchyma detected by CT as early as 1984 as a result of combined leukemia treatment of children with various drugs and radiation.21

Few existing studies investigating the therapeutic consequences of childhood brain tumors focus predominantly on volumetric measurements of the brain parenchyma or volume changes of specific brain regions. These frequently observed volume reductions of the hippocampus or white matter are associated with a memory dysfunction or decreased attentional abilities. According to Palmer et al., the extent of the volume reductions could be associated with the irradiation dose.22-25

Steen et al. investigated T1 effects on gray and white matter by ionizing radiation in conformal radiation therapy and found that T1 mapping may be sensitive to radiation-related changes in human brain tissue.26

Therapy-related changes differ from normal brain changes. They display different signal strength, different content, and a different binding of hydrogen atoms, so they are easily recognizable with a T2 sequence.27,28

Among 134 patients in a study by Folulardi et al. with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET) treated prospectively with risk-adjusted craniospinal irradiation and conformal boost to the tumor bed, followed by four high-dose chemotherapy cycles with stem-cell rescue, 22 developed white matter lesions (WMLs) on T1-weighted imaging with and without contrast and/or T2-weighted imaging at a median of 7.8 months after starting therapy. Lesions were predominantly in the pons and cerebellum. Sixteen patients had WML resolution at a median of 6.2 months after onset; two patients developed necrosis and atrophy.27

Early therapy-induced changes occurred from 3 weeks to a few months after irradiation and were characterized by T2 hyperintensity of the white matter, usually without increases over time. These changes may have been due to demyelination or edema.27-29 However, these are often not clearly defined. Johannesen et al. showed that late radiation-induced changes, as signal changes with or without enhancement, necrosis, and mass effects in T1 and T2, appear from several months to years after irradiation.19 Regarding our study, circa 50% of the patients had early therapy-induced changes only few months after CRT, whereas the first MRI changes were observed in the other 50% only after several years. It should be kept in mind, that the first MRI examination after irradiation usually took place after 2 and 6 months, so early, temporary changes in some cases might be missed by the lack of an earlier examination. The T2-signal changes in the posterior fossa frequently observed in our study can be explained by the irradiation boost of the tumor target region in addition to whole brain irradiation in medulloblastomas, which are usually located infratentorially. Although not specifically measured in our study, some of the patients with cerebellar T2-signal changes had worse motor functions than in previous studies, for example by Ciesielski et al.30

As previously reported by several authors,5,31,32 radiation-induced cavernous hemangiomas were found in almost one third of the long-term survivors in our study group. The four patients with signal reduction, a sign of micro-bleeding, were rather older. It is noticeable that the change only becomes apparent for some time after irradiation.

Several authors reported a link between age at CRT and the severity of parenchymal changes,9,19,33 a presumption we could not substantiate in our investigation. This could be explained by the small sample of patients less than 6 years of age who underwent whole brain irradiation. However, in our study group, cystic changes were only observed in two very young patients (under 6 years of age). Furthermore, the youngest patient showed very early signal changes at the first

Table 2 A quantitative listing of the respective deleted MRI changes of the brain parenchyma and the corresponding percentage listing

| MRI assessment of volume taken to full-dose of median 52.43 Gy (range 35.2-100 Gy) in 16 CNS tumor patients | n (%) |
|-------------------------------------------------|------|
| Atrophy                                         | 9 (60) |
| T2-increase                                     | 11 (73) |
| Contrast enhancement                            | 3 (20) |
| Malignancy (brain tumor, metastatic spread)     | 2 (13) |
| Cavernoma (signal loss in T2*)                  | 4 (26) |
| Cystic changes                                  | 2 (13) |

© 2020 The Authors. Pediatrics International published by John Wiley & Sons Australia, Ltd on behalf of Japan Pediatric Society
MRI examination, which could be an indirect sign of more significant changes.

Several authors have previously described a positive correlation between the dose rate and the extent of parenchymal changes. In our study group, no significant correlation was observed between the dose and the extent of parenchymal changes, probably due to the limited number of patients.

Evidence of leukoencephalopathy has also been reported with patients receiving chemotherapy only, which makes it difficult to isolate the changes caused by irradiation or chemotherapy only or a combination of both. All of the patients underwent chemotherapy. Additionally, in most cases the primary tumor site is the posterior fossa, where the cerebellum has been subjected to primary tumor-related compression, surgical intervention, and full-dose radiation therapy.

Whole-brain radiation therapy is still very rare in pediatric patients and information on this is scarce. In particular there are hardly any studies on post-radiogenic changes in children under 5 years of age. Kitajima et al., however, describe an increased occurrence of cystic changes in very young patients after irradiation. In our study, children who were less than 5 years old, as to be expected, were underrepresented; a link between the age at the time of radiotherapy and the specific parenchymal changes could therefore not be confirmed.

A correlation between the age of the child or the length of the radiotherapy and the extent of the changes could not be confirmed in our sample. However, the only two patients who had cystic changes were under 6 years of age at the time of irradiation. The youngest patient at the time of irradiation also showed very early signal changes during its first MRI examination. It can be said that there was a trend to more severe brain parenchyma degeneration with cystic changes in the younger age group of children. Older patients are probably more prone to undergo vascular dysplasia with higher incidence of cavernous hemangiomas and micro-bleeding in this
group. Due to the small sample size of children treated with whole-brain irradiation in individual institutions, further studies are needed to confirm this trend (Figs 1–3).

Disclosure

The authors declare no conflict of interest.

Author contributions

All data generated or analyzed during this study are included in this published article. L.P. contributed to the conception and design of this study. S.K. performed the statistical analysis and drafted the manuscript. T.L. and P.B. critically reviewed the manuscript and supervised the whole study process. All authors read and approved the final manuscript.

References

1 Agbahiwe H, Rashid A, Horska A et al. A prospective study of cerebral, frontal lobe, and temporal lobe volumes and neuropsychological performance in children with primary brain tumors treated with cranial radiation. Cancer 2017; 123: 161–8.

2 Juratli TA, Qin N, Cahill DP, Filbin MG. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. Pharmacol. Ther. 2017; 182: 70–79. https://doi.org/10.1016/j.pharmthera.2017.08.006

3 Knab B, Connell PP. Radiotherapy for pediatric brain tumors: when and how. Expert Rev. Anticancer Ther. 2007; 7: S69–77.

4 Bindra RS, Wolden SL. Advances in Radiation Therapy in Pediatric Neuro-oncology. J. Child Neurol. 2016; 31: 506–16.

5 Koike T, Yanagimachi N, Ishiguro H et al. High incidence of radiation-induced cavernous hemangioma in long-term survivors who underwent hematopoietic stem cell transplantation with radiation therapy during childhood or adolescence. Biol. Blood Marrow Transplant. 2012; 18: 1090–8.

6 Li L, Mugikura S, Kunabe T et al. A comparative study of the extent of cerebral microvascular injury following whole-brain irradiation versus reduced-field irradiation in long-term survivors of intracranial germ cell tumors. Radiother. Oncol. 2015; 117: 302–7.

7 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005; 352: 987–96.

8 Creutzig UL, T. (11/2012) Leitlinie der Gesellschaft für Pädiatrische Onkologie und Hämatologie. In: awmf.org, (ed) 025/009, awmf.org.

9 Furtwängler R, Yilmaz U. Pädiatrische Hirntumoren. Der Radiologue. 2014; 54: 754–63.

10 Kortmann RD, Timmermann B, Taylor RE et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther. Onkol. 2003; 179: 585–97.

11 Semple BD, Blomgren K, Gimlin K, Ferriero DM, Noble-Haeusslein LJ. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Prog. Neurobiol. 2013; 106–107: 1–16.

12 awmf.org (2018) S1-Leitlinie 025/009.

13 Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10: 293–310.

14 Rashid A, Ram AN, Kates WR et al. A prospective study of corpus callosum regional volumes and neurocognitive outcomes following cranial radiation for pediatric brain tumors. Childs Nerv. Syst. 2017; 33: 965–72.

15 Warrington JP, Csiszar A, Mitschelen M, Lee YW, Sonntag WE. Whole brain radiation-induced impairments in learning and memory are time-sensitive and reversible by systemic hypoxia. PLoS One 2012; 7: e30444.

16 Gastelum E, Sear K, Hills N et al. Rates and characteristics of radiographically detected intracerebral cavernous malformations after cranial radiation therapy in pediatric cancer patients. J. Child Neurol. 2015; 30: 842–9.

17 Di Giannatale A, Morana G, Rossi A et al. Natural history of cavernous malformations in children with brain tumors treated with radiotherapy and chemotherapy. J. Neurooncol. 2014; 117: 311–20.

18 Cutsforth-Gregory JK, Lanzino G, Link MJ, Brown RD Jr, Fleming KD. Characterization of radiation-induced cavernous malformations and comparison with a nonradiation cavernous malformation cohort. J. Neurosurg. 2015; 122: 1214–22.

19 Johannesen TB, Lien HHI, Hole KH, Lote K. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother. Oncol. 2003; 69: 169–76.

20 Pearce MS, Salotti JA, Little MP et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 380:499–505.

21 Robain O, Dulac O, Dommergues JP et al. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. J. Neurol. Neurosurg. Psychiatry. 1984; 47: 65–72.

22 Nagel BJ, Palmer SL, Reddick WE et al. Abnormal Hippocampal Development in Children with Medulloblastoma Treated with Risk-Adapted Irradiation. Am. J. Neuroradiol. 2004; 25: 1575–82.

23 Palmer SL, Reddick WE, Glass JO, Gajjar A, Goloubeva O, Mulhern RK. Decline in corpus callosum volume among pediatric patients with medulloblastoma: longitudinal MR imaging study. Am. J. Neuroradiol. 2002; 23: 1088–94.

24 Reddick WE, Glass JO, Palmer SL et al. Atypical white matter volume development in children following craniospinal irradiation. Neuro. Oncol. 2005; 7: 12–9.

25 Reddick WE, White HA, Glass JO et al. Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors. Cancer 2003; 97: 2512–19.

26 Steen RG, Koury BSM, Granja CI et al. Effect of ionizing radiation on the human brain: white matter and gray matter T1 in pediatric brain tumor patients treated with conformal radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 79–91.

27 Fouladi M, Chintagumpala M, Lanningham FH et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J. Clin. Oncol. 2004; 22: 4551–60.

28 Dietrich U, Wanke I, Mueller T et al. White matter disease in children treated for malignant brain tumors. Childs’ Nerv. Syst. 2001; 17: 731–8.

29 Kellie SJ, Chaku J, Lockwood LR, O’Regan P, Waters KD, Wong CK. Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy. Eur. J. Cancer 2005; 41: 1588–96.

30 Ciesielski KT, Yanofsky R, Ludwig RN et al. Hypoplasia of the cerebellar vermis and cognitive deficits in survivors of childhood leukemia. Arch. Neurol. 1994; 51: 985–93.
31 Porto L, Schoning S, Hattingen E, Sorensen J, Jurcoane A, Lehrnbecher T. Central nervous system imaging in childhood Langerhans cell histiocytosis – a reference center analysis. Radiol. Oncol. 2015; 49: 242–9.

32 Peters S, Pahl R, Claviez A, Jansen O. Detection of irreversible changes in susceptibility-weighted images after whole-brain irradiation of children. Neuroradiology 2013; 55: 853–9.

33 Giantsoudi D, Sethi RV, Yeap BY et al. Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. Int. J. Radiat. Oncol. Biol. Phys. 2016; 95: 287–96.

34 Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat. Res. 2010; 174: 840–50.

35 Kitajima M, Hirai T, Maruyama N et al. Asymptomatic cystic changes in the brain of children after cranial irradiation: frequency, latency, and relationship to age. Neuroradiology 2007; 49: 411–7.

36 Purdy E, Johnston DL, Bartels U et al. Ependymoma in children under the age of 3 years: a report from the Canadian Pediatric Brain Tumour Consortium. J. Neurooncol. 2014; 117: 359–64.

37 Koshy M, Rich S, Merchant TE, Mahmood U, Regine WF, Kwok Y. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J. Neurooncol. 2011; 105: 583–90.

38 Goldwein JW, Radcliffe J, Packer RJ et al. Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. Cancer 1993; 71: 2647–52.